Semaglutide

Description

DESCRIPTION

Semaglutide is a long‑acting GLP‑1 receptor agonist engineered with specific amino‑acid substitutions and a C18 fatty‑acid chain to enhance metabolic stability and extend circulating half‑life. Research explores its influence on glucose homeostasis, pancreatic β‑cell responses, gut–brain appetite signaling, energy‑balance pathways, cardiometabolic markers, and endocrine‑regulated mechanisms. All findings referenced are strictly for laboratory and mechanistic research models.

LYOPHILIZED PEPTIDES

This peptide is supplied in freeze‑dried (lyophilized) form to maintain purity, structural integrity, and storage stability. No fillers or excipients are used.

RESEARCH APPLICATIONS

1 — Glucose Regulation & GLP‑1 Receptor Pathways

Semaglutide is widely used in research to evaluate GLP‑1–mediated insulin secretion, glucagon suppression, hepatic glucose output, and metabolic signaling circuitry. Its long‑acting structure allows modeling of sustained incretin‑pathway effects.

(References: Nature—https://www.nature.com/articles/s41591-023-02590-2, PubMed—https://pubmed.ncbi.nlm.nih.gov/37365087/ )

2 — Appetite, Satiety & Weight‑Regulation Mechanisms

Laboratory models apply semaglutide to investigate gut‑brain axis signaling, appetite modulation, satiety responses, energy intake, and weight‑regulation pathways involving GLP‑1–dependent receptor circuits.

(References: ScienceDirect—https://www.sciencedirect.com/science/article/pii/S1550413123002073, PubMed—https://pubmed.ncbi.nlm.nih.gov/37581871/ )

3 — Cardiometabolic & Inflammatory Pathway Research

Studies examine semaglutide’s effects on inflammation markers, endothelial signaling, oxidative‑stress responses, lipid metabolism, and long‑term cardiometabolic modeling. Its incretin‑based mechanism provides broad relevance for systemic metabolic research.

(References: MDPI—https://www.mdpi.com/1422-0067/24/3/2341, PubMed—https://pubmed.ncbi.nlm.nih.gov/36638174/ )

4 — Comparative Incretin & Multi‑Agonist Modeling

Semaglutide is commonly used as a reference tool in research evaluating dual agonists, triple agonists, and variant GLP‑1 analogues for receptor‑selectivity, half‑life modifications, and metabolic outcomes.

(References: Frontiers—https://www.frontiersin.org/articles/10.3389/fendo.2023.1211441/full, PubMed—https://pubmed.ncbi.nlm.nih.gov/36971244/ )

SPECIFICATIONS

Property | Details

Peptide Name | Semaglutide

Type | GLP‑1 Receptor Agonist

Amino Acid Length | 31‑amino‑acid modified GLP‑1 analogue

CAS Number | 910463‑68‑2

Molecular Formula | C187H291N45O59

Molecular Weight | ~4113.6 Da

Purity | ≥ 99% (HPLC verified)

Appearance | White to off‑white lyophilized powder

Solubility | Soluble in sterile/bacteriostatic water

Storage | Store frozen at −20 °C; protect from light

Usage | Laboratory research only

Research Data & References

– GLP‑1 metabolic pathway studies: https://pubmed.ncbi.nlm.nih.gov/37365087/

– Glycemic stability & endocrine signaling: https://pubmed.ncbi.nlm.nih.gov/37581871/

– Hepatic/lipid metabolic models: https://pubmed.ncbi.nlm.nih.gov/36638174/

Disclaimer — Research Use Only

All information presented herein is intended solely for laboratory and educational research. These materials are not approved for human or veterinary use, nor for diagnostic or therapeutic application. Descriptions of biochemical activity are provided for informational context only and must not be interpreted as medical advice. Researchers are expected to handle all compounds in compliance with local regulations and institutional safety standards. EOC Labs supports responsible, ethical, and compliant scientific inquiry.